Association between blood transfusion after kidney transplantation and risk for the development of de novo HLA donor-specific antibodies and poor clinical outcomes: A single-center retrospective study
Transplant Immunology · 2023-12 · 81 · 101930
DOI: 10.1016/j.trim.2023.101930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Immunology, 2023-12. Verfasst von Zhong-Yu Kang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Transfusion, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, Nankai, China. Hauptthemen laut MEDLINE: Kidney Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Blood transfusion after kidney transplantation may increase the risk of sensitization and development of de novo human leukocyte antigen (HLA) donor-specific antibodies (DSAs). This study aimed to evaluate whether blood transfusion during the first year after kidney transplantation influences the development of de novo DSAs and clinical outcomes of kidney transplantation recipients. METHODS: This retrospective cohort study included nonsensitized first-time kidney transplantation recipients at Tianjin First Central Hospital from 2010 to 2022. The incidence of de novo DSA development and clinical outcomes between the groups were compared. Luminex single antigen beads were used to monitor DSAs. RESULTS: Of the 538 non-HLA-sensitized kidney transplantation recipients included in the study, 164 patients who received at least one unit of leukoreduced red blood cell transfusion within the first year (the transfused group), whereas the remaining 374 patients received no blood transfusion (the non-transfused group). Our analysis showed that there was a significant difference in the development of de novo DSAs and de novo anti-class I HLA-Ab between the two groups. Indeed, the transfused recipients had a higher serum creatinine and lower estimated glomerular filtration rate (eGFR) at 1-, 6-, and 12-month (all p > 0.05) after transplantation. Futhermore, a higher incidence of CMV infection, antibody-mediated rejection (AMR), hyper acute rejection (HAR), and delayed graft function (DGF) was identified in the transfused group (all p < 0.05). The graft survival was lower in the transfused group compared with patients in the non-transfused group (P = 0.002). Blood transfusion post-transplantation was a risk factor for de novo DSAs development but not an independent predictive factor for AMR and graft loss (odds ratio = 2.064 [1.243-3.429], p = 0.005). CONCLUSIONS: Our study showed that blood transfusion after transplantation is associated with the occurrence of de novo DSAs increasing an immunological risk for poor clinical outcomes for kidney transplantation recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Blood Transfusion, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, Nankai, China.
- Department of Blood Transfusion, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, Nankai, China. Electronic address: ldh_hla@126.com.
Zitieren
APA
Kang, Z. Y., Liu, C., Liu, W., & Li, D. (2023). Association between blood transfusion after kidney transplantation and risk for the development of de novo HLA donor-specific antibodies and poor clinical outcomes: A single-center retrospective study. Transplant Immunology, 81, 101930. https://doi.org/10.1016/j.trim.2023.101930
Vancouver
Kang ZY, Liu C, Liu W, Li D. Association between blood transfusion after kidney transplantation and risk for the development of de novo HLA donor-specific antibodies and poor clinical outcomes: A single-center retrospective study. Transplant Immunology. 2023;81:101930. doi:10.1016/j.trim.2023.101930
BibTeX
@article{Kang2023,
author = {Kang, Zhong-Yu and Liu, Chun and Liu, Wei and Li, Daihong},
title = {Association between blood transfusion after kidney transplantation and risk for the development of de novo HLA donor-specific antibodies and poor clinical outcomes: A single-center retrospective study},
journal = {Transplant Immunology},
year = {2023},
volume = {81},
pages = {101930},
doi = {10.1016/j.trim.2023.101930}
}
EUVIMED